Should the consumption of survivors be included as a cost in cost-utility analysis?

Health Economics

Volumn 13, Issue 5, 2004, Pages 417-427

  Nyman, John A ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Cost utility analysis; Recuperation time costs; Survival consumption costs; Unrelated medical care costs; Welfare economics

Indexed keywords

ARTICLE; COST CONTROL; COST UTILITY ANALYSIS; HEALTH CARE COST; HEALTH ECONOMICS; PRIORITY JOURNAL; STANDARDIZATION; SURVIVAL; WELFARE;

COST-BENEFIT ANALYSIS; HEALTH EXPENDITURES; HUMANS; MODELS, THEORETICAL; QUALITY-ADJUSTED LIFE YEARS; SURVIVORS; UNITED STATES;

EID: 2442702844     PISSN: 10579230     EISSN: None     Source Type: Journal    
DOI: 10.1002/hec.850     Document Type: Article

References (25)

1. Weinstein MC, Fineberg HV, Elstein AS et al. Clinical Decision Analysis. Philadelphia: W. B. Saunders, 1980.
2. Drummond MF, O'Brien B, Stoddart GL, Torrence GW. Methody for the Economic Evaluation of Health Care Programmes (2nd edn). Oxford: Oxford, 1997.
3. Mushlin AI, Fintor L. Is screening for breast cancer cost-effective'? Cancer 1992, 69(Suppl.): 1957-1962.
4. Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ 1997; 16: 1-31.
5. Gold MR, Siegel JE, Russell LB, Weinstein MC (eds). Cost-effectiveness in Health and Medicine. Oxford: Oxford, 1996.
6. Russell LB. Is Prevention Better than Cure? Brookings: Washington, 1986.
7. Weinstein MC. Challenges for cost-effectiveness research. Med Dec Making 1986: 194-198.
8. Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 1997; 16: 33-64.
9. Mishan EJ. Cost-Benefit Analysis: An Introduction. Praeger: New York, 1971.
10. Stason WB, Weinstein MC. Allocation of Resources to manage hypertension. N Engl J Med 1977; 296: 732-739.
11. Kaplan RM, Ganiats TG, Sieber WJ. Quality of Well-Being Scale, Self-Administered, QWB-SA, V1.04., 1996.
12. EuroQol Group. EuroQol: A new facility for the measurement of health-related quality of life. Health Policy 1990: 16: 199-208.
13. Feeny D, Furlong W, Boyle M, Torrance GW. Multi-attribute health status classification systems. Pharmacoecon 1995; 7: 490-502.
14. Johannesson M, Jonsson B, Kjekshus J, Olsson AG, Pederson TR, Wedel H. Cost-effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997; 336: 332-336.
15. Nyman JA, Martinson M, Nelson D et al. Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol. Arch Int Med 2002: 162: 177-182.
16. Drummond M, McGuire A, Fletcher A. Economic Evaluation of Drug Therapy for Hypercholesterolaemia in the United Kingdom. Center for Health Economics Discussion Paper 104. University of York: York, 1993.
17. Culyer AJ. The normative economics of healthcare finance and provision. In Providing HealthCare, McGuire A, Fenn P, Mayhew K (eds). Oxford University Press: Oxford, 1991.
18. Williams A. Cost-benefit analysis: applied welfare economics or general decision aid. In Efficiency in the Public Sector, Williams A, Giardina E (eds). Edward Elgar: London, 1993,
19. Sen A. The possibility of social choice. Am Econ Rev 1999: 89: 349-378.
20. McGuire A. Theoretical concepts in the economic evaluation of health care. In Economic Evaluation in Health Care, Drummond M, McGuire A (eds). Oxford University Press: Oxford, 2001.
21. Kaplan RM, Anderson JP. The general heatlh policy model: an intergrated approach. In Quality of Life and Pharmacoeconomics in Clinical Trials (2nd edn), Spilker B (ed). Lippincott -Raven: Philadelphia, 1996.
22. Brazier J, Jones N, Kind P. Testing the validity of the Euroqol and comparing it with the SF-36 Health Survey questionnaire. Qual Life Res 1993; 2: 169-180.
23. Brazier J, Usherwood T, Harper R, Thomas K. Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epi 1998; 51: 1115-1128.
24. Fryback DG, Lawrence WF, Martin PA, Klein R, Klein BEK. Predicting Quality of Well-being scores from the SF-36: results from the Beaver Dam Health Outcomes Study. Med Dec Making 1997; 17: 1-9.
25. Nichol MB, Sengupta N, Globe DR. Evaluating quality-adjusted life years: estimation of the Health Utility Index (HUI2) from the SF-36. Med Dec Making 2001; 21: 105-112.